Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Renal Cell Carcinoma: Update Bulletin #2 [December 2018]

Product Code:
596201030
Publication Date:
December 2018
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the renal cell carcinoma (RCC) market, including: Positive data reported at ESMO 2018 from the Phase III JAVELIN Renal 101 trial, investigating avelumab (Bavencio; Merck Group/Pfizer) in combination with axitinib (Inlyta; Pfizer) as first-line treatment for advanced RCC; the combination of pembrolizumab (Keytruda; Merck & Co.) plus axitinib meeting its co-primary endpoints in the KEYNOTE-426 trial, in the first-line treatment of advanced RCC; positive early data presented at ESMO 2018 from the Phase Ib COSMIC-021 trial investigating the combination of cabozantinib (Cabometyx; Exelixis/Ipsen) and atezolizumab (Tecentriq; Roche) in patients with previously untreated advanced RCC.

Business Questions:

• How do KOLs view the data presented at ESMO 2018 from the Phase III JAVELIN Renal 101 trial of avelumab in combination with axitinib?
• Do KOLs expect avelumab plus axitinib to be a first-line option for the treatment of RCC?
• According to experts, do current data support the use of avelumab plus axitinib based on PD-L1 status?
• Could the safety profile of the avelumab/axitinib present a barrier to its use?
• How do KOLs interpret the findings from the Phase III KEYNOTE-426 trial of pembrolizumab plus axitinib?
• Do specialists expect pembrolizumab plus axitinib will be able to differentiate itself effectively, based on its OS benefits?
• What other factors will influence the success of tyrosine kinase inhibitor/PD-L1 inhibitor combinations in RCC?
• Do the experts find early data on the efficacy of the cabozantinib plus atezolizumab combination encouraging?
• What hurdles could the cabozantinib plus atezolizumab combination face?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved